Prenetics Global Ltd

Prenetics Global Ltd. engages in the provision of preventive and diagnostic health testing and services. It operates through the following segments: Prevention, Diagnostics, and Personalized Care. The Prevention segment delivers genetic testing services to individuals and corporate entities. The Diagnostics segment includes COVID-19 testing services for individuals, corporate clients, and governments for community testing. The Personalized Care segment offers personalized nutrition, hair loss, and sexual health products tailored to each of customer's individual and genetic variation and biology. The company was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and is headquartered in Hong Kong.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prenetics Global Limited is a health sciences company, which engages in the provision of early detection, prevention, and treatment of cancer. The firm offers products and services under the brands of CircleDNA, Insighta, ACT Genomics, IM8, and Europa. IM8, a health and wellness brand which focuses on consumer health products. Europa, a U.S. sports distribution company. Insighta, a venture which focuses on the development of early cancer detection technologies. It also focuses on its CircleDNA and ACT Genomics business units. The CircleDNA business unit uses next-generation sequencing (NGS) technology for consumer deoxyribonucleic acid (DNA) test. The ACT Genomics business unit is involved in genomic profiling of solid tumors. It has a presence in the United States. The company was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and is headquartered in Hong Kong.

Beckham is a strategic investor in Prenetics and Co-Founding Partner for IM8 IM8 launch marks a bold entry into the $187 billion global consumer health market Launch follows recently announced Prenetics' acquisition of Europa, one of the largest sports nutrition distributors in the U.S. IM8 is now available at www.IM8health.com , shipping to 31 countries (David Beckham pictured with The Beckham Stack) CHARLOTTE, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, in partnership with David Beckham, today announced the official launch of IM8.

MULTIMEDIA UPDATE -- Nasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health

Beckham is a strategic investor in Prenetics and Co-Founding Partner for IM8 IM8 launch marks a bold entry into the $187 billion global consumer health market Launch follows recently announced Prenetics' acquisition of Europa, one of the largest sports nutrition distributors in the U.S. IM8 is now available at www.IM8health.com , shipping to 31 countries CHARLOTTE, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, in partnership with David Beckham, today announced the official launch of IM8.

Nasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health

CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on November 13-14, 2024.

Prenetics Announces Participation in the Sidoti Virtual Micro Cap Investor Conference

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners (“Europa”) and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider.

Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

LOS ANGELES, July 11, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, is proud to announce that former international footballer, entrepreneur and philanthropist David Beckham has become a strategic investor in the business. Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on cutting-edge consumer health products, with details to be announced at a later date.

Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham

Adding Decades of Public Company and Board Expertise as Prenetics Readies for Expansion into Consumer Health and Wellness Adding Decades of Public Company and Board Expertise as Prenetics Readies for Expansion into Consumer Health and Wellness

Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter

Prenetics Announces First Quarter 2024 Financial Results

HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.

Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results

(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency)

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.

Prenetics Announces Third Quarter 2023 Financial Results

HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split of its outstanding ordinary shares at a ratio of 1-for-15.

Prenetics Global Limited Announces Reverse Stock Split

HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.

Prenetics Announces Second Quarter 2023 Financial Results

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Prenetics Global Limited (PRE) Is Considered a Good Investment by Brokers: Is That True?

Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT

Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening

Wall Street Analysts See Prenetics Global Limited (PRE) as a Buy: Should You Invest?

HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates.

Prenetics Announces First Quarter 2023 Financial Results

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Should You Invest in Prenetics Global Limited (PRE) Based on Bullish Wall Street Views?

Fathom Holdings

Magic Software Enterprises

Rush Street Interactive

VAALCO Energy

Lovesac Company

OmniAb Inc

If Warren Buffett was your financial advisor, he might steer you toward reliable blue-chip investments, not wildly speculative stocks to buy now. Put another way, you're probably not going to find these enterprises listed among the holdings of Berkshire Hathaway (NYSE: BRK-B ).

7 Stocks to Buy for Their Massive Upside Potential

Prenetics Global Limited (PRE) closed the most recent trading day at $0.89, making no change from the previous trading session.

Prenetics Global Limited (PRE) Flat As Market Gains: What You Should Know

Wall Street Analysts Look Bullish on Prenetics Global Limited (PRE): Should You Buy?

Harrow Health Inc

Lisata Therapeutics Inc

Ocuphire Pharma

We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.

4 Medical Stocks to Buy as Rate Hike Cycle Nears End

Prenetics Global Limited (PRE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Prenetics Global Limited (PRE) Loses -24.21% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

New Business Strategy Focused on Precision Oncology New Business Strategy Focused on Precision Oncology

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the ‘SAB') to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform.

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to February 16, 2023.

News for Prenetics Global Ltd Stock (PRE)